دورية أكاديمية
أعرض في EDS

A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival.

التفاصيل البيبلوغرافية
العنوان: A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival.
المؤلفون: Halle MK; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5053 Bergen, Norway.; Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5053 Bergen, Norway., Munk AC; Department of Obstetrics and Gynaecology, Sørlandet Hospital Kristiansand, 4604 Kristiansand, Norway., Engesæter B; Section for Cervical Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway., Akbari S; Department of Pathology, Stavanger University Hospital, 4068 Stavanger, Norway., Frafjord A; Department of Pathology, Stavanger University Hospital, 4068 Stavanger, Norway., Hoivik EA; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5053 Bergen, Norway.; Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5053 Bergen, Norway., Forsse D; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5053 Bergen, Norway.; Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5053 Bergen, Norway., Fasmer KE; Section for Radiology, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway.; Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, 5021 Bergen, Norway., Woie K; Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5053 Bergen, Norway., Haldorsen IS; Section for Radiology, Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway.; Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, 5021 Bergen, Norway., Bertelsen BI; Department of Pathology, Haukeland University Hospital, 5021 Bergen, Norway., Janssen EAM; Department of Pathology, Stavanger University Hospital, 4068 Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Technology, University of Stavanger, 4036 Stavanger, Norway., Gudslaugsson E; Department of Pathology, Stavanger University Hospital, 4068 Stavanger, Norway., Krakstad C; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5053 Bergen, Norway.; Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5053 Bergen, Norway., Øvestad IT; Department of Pathology, Stavanger University Hospital, 4068 Stavanger, Norway.
المصدر: Cancers [Cancers (Basel)] 2021 Nov 16; Vol. 13 (22). Date of Electronic Publication: 2021 Nov 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: The purpose of this study was to establish a gene signature that may predict CIN3 regression and that may aid in selecting patients who may safely refrain from conization. Oncomine mRNA data including 398 immune-related genes from 21 lesions with confirmed regression and 28 with persistent CIN3 were compared. L1000 mRNA data from a cervical cancer cohort was available for validation ( n = 239). Transcriptomic analyses identified TDO2 ( p = 0.004), CCL5 ( p < 0.001), CCL3 ( p = 0.04), CD38 ( p = 0.02), and PRF1 ( p = 0.005) as upregulated, and LCK downregulated ( p = 0.01) in CIN3 regression as compared to persistent CIN3 lesions. From these, a gene signature predicting CIN3 regression with a sensitivity of 91% (AUC = 0.85) was established. Transcriptomic analyses revealed proliferation as significantly linked to persistent CIN3. Within the cancer cohort, high regression signature score associated with immune activation by Gene Set enrichment Analyses (GSEA) and immune cell infiltration by histopathological evaluation ( p < 0.001). Low signature score was associated with poor survival ( p = 0.007) and large tumors ( p = 0.01). In conclusion, the proposed six-gene signature predicts CIN regression and favorable cervical cancer prognosis and points to common drivers in precursors and cervical cancer lesions.
References: Br J Cancer. 1991 Sep;64(3):559-65. (PMID: 1911199)
Int J Cancer. 2006 Mar 15;118(6):1481-95. (PMID: 16206285)
Acta Obstet Gynecol Scand. 1998 May;77(5):558-63. (PMID: 9654180)
Int J Oncol. 2020 Jul;57(1):338-354. (PMID: 32319590)
Int J Cancer. 2013 Feb 15;132(4):854-67. (PMID: 22752992)
Nat Commun. 2013;4:2612. (PMID: 24113773)
Gynecol Oncol. 2012 Dec;127(3):489-94. (PMID: 23017821)
Gynecol Obstet Invest. 2019;84(6):562-567. (PMID: 31055567)
Front Oncol. 2019 Aug 02;9:682. (PMID: 31428574)
Mol Carcinog. 2017 Oct;56(10):2245-2257. (PMID: 28544069)
J Natl Cancer Inst. 2008 Apr 2;100(7):513-7. (PMID: 18364507)
Lancet. 2007 Nov 10;370(9599):1609-21. (PMID: 17993361)
Int J Gynecol Cancer. 2019 Jul;29(6):1003-1009. (PMID: 31079058)
Int J Gynecol Pathol. 1993 Apr;12(2):186-92. (PMID: 8463044)
Arch Pathol Lab Med. 2020 Jun;144(6):725-734. (PMID: 31718233)
Hum Pathol. 2016 May;51:64-74. (PMID: 27067784)
Lancet Oncol. 2008 May;9(5):425-34. (PMID: 18407790)
Cancer. 1950 Jan;3(1):32-5. (PMID: 15405679)
Gynecol Oncol. 1995 Oct;59(1):143-7. (PMID: 7557600)
Clin Cancer Res. 2005 Jul 1;11(13):4717-23. (PMID: 16000566)
Cancer Cytopathol. 2019 Sep;127(9):586-597. (PMID: 31412167)
Exp Mol Pathol. 2013 Oct;95(2):166-73. (PMID: 23791892)
BMJ. 2018 Feb 27;360:k499. (PMID: 29487049)
Biochem Biophys Res Commun. 2010 Nov 26;402(4):631-6. (PMID: 20971076)
Sex Transm Dis. 2015 Jan;42(1):20-6. (PMID: 25504296)
Gynecol Oncol. 2021 Sep;162(3):569-574. (PMID: 34226019)
Int J Cancer. 2019 Nov 15;145(10):2629-2638. (PMID: 30734284)
Int J Gynaecol Obstet. 2016 Mar;132(3):266-71. (PMID: 26643302)
BMJ. 2008 Sep 18;337:a1343. (PMID: 18801869)
Sex Transm Infect. 2018 Nov;94(7):522-527. (PMID: 29523719)
Am J Obstet Gynecol. 2017 Oct;217(4):432.e1-432.e17. (PMID: 28599900)
Gynecol Oncol. 2021 Aug;162(2):299-307. (PMID: 34116834)
Arch Sex Behav. 2010 Aug;39(4):907-14. (PMID: 19330437)
Bioinformatics. 2001 Apr;17(4):369-70. (PMID: 11301307)
Infect Agent Cancer. 2012 Nov 05;7(1):30. (PMID: 23126423)
PLoS One. 2012;7(9):e45114. (PMID: 23028792)
Cells. 2019 Dec 24;9(1):. (PMID: 31878283)
J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9. (PMID: 16030305)
BMJ. 2008 Sep 18;337:a1284. (PMID: 18801868)
Lancet. 2007 Sep 8;370(9590):890-907. (PMID: 17826171)
Int J Cancer. 2019 Apr 15;144(8):1975-1982. (PMID: 30246864)
Cell. 2017 Nov 30;171(6):1437-1452.e17. (PMID: 29195078)
J Natl Cancer Inst. 2000 May 3;92(9):690-8. (PMID: 10793105)
Int J Cancer. 2006 Sep 1;119(5):1108-24. (PMID: 16570271)
Clin Microbiol Infect. 2020 May;26(5):579-583. (PMID: 31539637)
Nat Rev Immunol. 2015 Jun;15(6):388-400. (PMID: 25998963)
Front Immunol. 2019 Sep 04;10:2093. (PMID: 31552039)
Oncogene Res. 1987 Sep-Oct;1(4):357-74. (PMID: 2835736)
Lancet. 2019 Jan 12;393(10167):169-182. (PMID: 30638582)
J Natl Cancer Inst. 1999 Feb 3;91(3):252-8. (PMID: 10037103)
Oncoimmunology. 2015 Feb 25;4(2):e981457. (PMID: 25949879)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
Obstet Gynecol. 2012 Dec;120(6):1465-71. (PMID: 23168774)
Nat Commun. 2020 Apr 24;11(1):1999. (PMID: 32332850)
BJOG. 2020 May;127(6):729-736. (PMID: 31880054)
J Biol Chem. 2006 Apr 21;281(16):11322-31. (PMID: 16474166)
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502. (PMID: 22308364)
Clin Cancer Res. 2001 Feb;7(2):285-9. (PMID: 11234881)
Br J Cancer. 2010 Sep 7;103(6):899-909. (PMID: 20717116)
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5958-62. (PMID: 8650201)
Medicine (Baltimore). 2020 Nov 13;99(46):e23155. (PMID: 33181688)
Nat Rev Drug Discov. 2019 May;18(5):379-401. (PMID: 30760888)
Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60. (PMID: 15298958)
Cancer Discov. 2021 Aug;11(8):1896-1912. (PMID: 33990345)
Syst Rev. 2019 Jun 7;8(1):132. (PMID: 31174598)
BMJ. 2016 Jul 28;354:i3633. (PMID: 27469988)
Lancet. 2014 Feb 8;383(9916):524-32. (PMID: 24192252)
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. (PMID: 23199969)
J Immunother Cancer. 2020 Aug;8(2):. (PMID: 32847986)
Br J Cancer. 2021 May;124(10):1690-1698. (PMID: 33723390)
J Clin Pathol. 2011 Apr;64(4):303-7. (PMID: 21421698)
Cancer Res. 2005 Apr 1;65(7):2921-9. (PMID: 15805295)
Int J Mol Sci. 2019 Jul 16;20(14):. (PMID: 31315298)
Obstet Gynecol. 2021 Jun 1;137(6):1043-1053. (PMID: 33957649)
Int J Mol Sci. 2020 Oct 15;21(20):. (PMID: 33076281)
معلومات مُعتمدة: Year 2017-2019 Folke Hermansen; 27804 and 911634 Western Norway Regional Health Authority; Annual University of Bergen; 273280 The Research Council of Norway; 190202 Norwegian Cancer Society
فهرسة مساهمة: Keywords: CD38; HPV test; LCK; cervical cancer; cervical intraepithelial neoplasia (CIN); conization; gene expression analyses; immune activation; perforin; prognostic biomarker
تواريخ الأحداث: Date Created: 20211127 Latest Revision: 20211130
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8616457
DOI: 10.3390/cancers13225737
PMID: 34830895
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13225737